title: [Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer].
abstract: OBJECTIVE
  To evaluate the efficacy of accelerated hyperfractionation (CAF) radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer.
  
  
  METHODS
  Between June 2004 and January 2008, 53 patients with locoregional recurrent rectal cancer were treated with CAF 1.2 Gy/f, 2 f/d plus concurrent capecitabine at an oral dosage of 825 mg/m2 bid on each day of radiotherapy period. The first daily dose was applied at 2 h pre-irradiation, d1-14 and d22-35. After a regimen of 36 Gy/30 f/3 w, the feasibility of surgical resection was then evaluated by CT. Patients unsuitable for surgical resection continued CAF. And the total dose was 52.8-57.6 Gy.
  
  
  RESULTS
  The complete response rate was 9.8%, the partial response rate 45.1%, the effective rate 54.9%, the no-change rate 29.4%, the progression rate 15.7%, the surgical resection rate 23.5% and the R0, R1 resection rates 21.6% and 1.9% respectively. The Time to Progression was 10.5 months, 1-year survival rate was 84.3%, 2-year survival rate was 61.1%. Quality of life improved in treatment group. Toxic and adverse effects were gastrointestinal and hematological toxicities. There was no treatment-related mortality.
  
  
  CONCLUSIONS
  The 3-dimensional conformal radiotherapy plus concurrent chemotherapy may be an effective and well-tolerated regimen in patients with postoperative locoregional recurrent or metastatic rectal cancer.
authors.affiliation: Department of Radiation Oncology, Qianfoshan Hospital, Shandong University, Jinan 250014, China.
authors.forename: Jian-dong
authors.initials: JD
authors.lastname: Zhang
authors.forename: Yong
authors.initials: Y
authors.lastname: Dai
authors.forename: Jin-ming
authors.initials: JM
authors.lastname: Yu
authors.forename: Zhen-yu
authors.initials: ZY
authors.lastname: Shao
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000532:radiotherapy*; D009367:Neoplasm Staging; D011379:Prognosis; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil